Weight loss that holds
Losing it is the straightforward part. This is clinician-led treatment built around keeping it off — your dose reviewed and adjusted as you go, not handed over and forgotten.
From £99.00 / month
Based on Wegovy Pill. Your price depends on the treatment and dose a clinician prescribes — from £99 to £149 a month.
- Four routes — two weekly injections, two daily tablets
- Reviewed by a registered clinician within 1 working day
- Up to 20.9% average weight loss in clinical trials1
Takes 4 minutes · If a clinician doesn’t prescribe, you’re refunded in full
All content on this page has been medically reviewed by Naeem Teni, Clinical Lead. GPhC 2215591.
Medication options
More than one route.
Mounjarotirzepatide
From £149.00 / month
Once weekly injection
A newer weekly treatment a clinician may consider depending on your health and history.
- 20.9% average weight loss over 72 weeks1
- Acts on two gut-hormone pathways, not one
- Pre-loaded pen — no needle to attach
Wegovysemaglutide
From £119.00 / month
Once weekly injection
One of the most established weekly options for medical weight management.
- 14.9% average weight loss over 68 weeks2
- The most widely studied of the weekly injections
- Pre-loaded pen — no needle to attach
Wegovy Pilloral semaglutide
From £99.00 / month
Once daily tablet
The newest route we offer, and an oral one, taken daily rather than weekly.
- 13.6% average weight loss over 64 weeks3
- The same medicine as the injection, taken by mouth
- One tablet a day, no needles
Foundayoorforglipron
Price confirmed at assessment
Once daily tablet
Another option a clinician may consider as part of your weight-management plan, depending on your health and history.
- 11.1% average weight loss over 72 weeks4
- A non-peptide tablet — taken any time of day
- No food or water timing rules
There isn’t a single “best” treatment, the right one depends on you. Here’s what a clinician may consider, though the final choice, and whether treatment is suitable at all, is always theirs to make with you.
BMI check
Where does your BMI land?
Your result and what it means will appear here.
BMI is a guide, not a diagnosis, and it doesn't fit everyone (for example during pregnancy, or for very muscular people). A registered clinician makes the final decision about whether any treatment is appropriate for you.
The whole programme
Your weight-loss journey
Your assessment
- A four-minute online assessment
- Reviewed by a clinician, not a form
- Your wider health, not just the scale
Getting started
- A low starting dose, by design
- Support if you feel off while adjusting
- Free delivery, in plain packaging
The weight-loss phase
- Your dose reviewed and adjusted
- Portions start to feel smaller
- Refills arrive automatically
Ongoing support
- Any wind-down is gradual, never abrupt
- Cancel anytime, month to month
- A care team a message away
The people behind your care
Clinicians, not chatbots.
Medical Director
Clinical Lead
Head of Clinical Operations
The bit that isn't marketing.
Placeholder text. A short review sits here, about two lines, so you can see how the card looks at its smallest.
Placeholder text. This card carries a medium-length review, roughly four lines of body copy, which shows how the card grows and where the name settles underneath it.
Placeholder text. A longer review runs to about six lines, which is roughly the most this layout carries comfortably before the row starts to look unbalanced against the two cards beside it.
FAQs
The questions people actually ask.
How much weight will I actually lose?
Nobody can tell you your number in advance, and be wary of anyone who tries. What the clinical trials found, at the highest dose studied, alongside diet and activity support:
- Mounjaro (tirzepatide 15 mg, 72 weeks) — 20.9% average weight loss
- Wegovy (semaglutide 2.4 mg, 68 weeks) — 14.9%
- Wegovy Pill (oral semaglutide 25 mg, 64 weeks) — 13.6%
- Foundayo (orforglipron 36 mg, 72 weeks) — 11.1%
Those are averages across everyone who started, including people who stopped early, which is the honest way to read them and lower than the figures usually quoted. Some people lose considerably more. Some lose very little. Your starting weight, the dose you tolerate and what else changes alongside it all matter.
What happens when I stop?
Most of the weight comes back, and it is better to know that now than in a year.
When semaglutide was withdrawn in the STEP 1 trial extension, participants regained around two-thirds of what they had lost within twelve months — finishing 5.6% below where they started, having been 17.3% down at their lowest.
That is not a failure of willpower. These medicines work while they are in your system; when they leave, appetite returns to roughly where it was. It is why we treat this as long-term management rather than a course you finish, and why the plan puts weight on the parts that outlast the medication.
Do I have to inject myself?
No — two of the four options are tablets.
Mounjaro and Wegovy are once-weekly injections you give yourself with a pre-loaded pen. There is no needle to attach and no dose to draw up; it goes into the stomach, thigh or upper arm. Wegovy Pill and Foundayo are taken daily by mouth instead.
Which suits you is worth raising in your assessment. A dislike of needles is a perfectly good reason to prefer a tablet, and nobody here will make you feel odd about it.
Is Mounjaro better than Wegovy?
For weight loss, on average, yes — and unusually for this question it has been tested directly rather than inferred by comparing separate trials. In SURMOUNT-5, a head-to-head study, tirzepatide produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide.
“On average” is doing real work in that sentence. Averages describe groups, not people, and the better-performing medicine is not automatically the better choice for you — how well you tolerate it, your other conditions and medicines, cost, and how you feel about a weekly injection all count. That is a conversation with your clinician, not a league table.
Do I need a certain BMI?
Treatment is usually considered from a BMI of 30, or from 27 if you also have a weight-related condition such as high blood pressure or type 2 diabetes. There is a BMI checker further up this page.
BMI is a starting filter, not the decision. It is a crude measure — it cannot tell muscle from fat, and it reads differently across ethnic groups — so a clinician looks at your whole picture rather than one number.
What are the side effects in the first few weeks?
Mostly your gut, and mostly early. Nausea is the common one, along with constipation, diarrhoea, vomiting and reflux. They tend to appear when you start and each time your dose increases, and to settle as your body adjusts. Smaller portions, stopping when you are full rather than when the plate is, and going easy on rich food help more than people expect.
Less commonly these medicines can cause gallbladder problems or inflammation of the pancreas. Severe, persistent stomach pain, particularly if it goes through to your back with vomiting, needs urgent medical attention rather than a wait-and-see. Your clinician will go through the full list against your history before anything is prescribed.
Will a real clinician actually review me?
What if it's not right for me?
Guides
More on weight loss.
Weight loss medicines before surgery: UK guidance says continue
UK national guidance and US national guidance say opposite things, and some UK hospitals follow the US version anyway. The one instruction that holds …
Read →
Missed doses: the catch-up windows, product by product
Every product has a different rule, the oral tablet has no rule at all in the sense people expect, and the one thing none of them permit is taking two…
Read →
Injection technique and sites: what the UK recommendations actually say
Most of what goes wrong is not the needle going in. It is coming out too early, going back into the same square inch every week, or a used pen with no…
Read →References
- SURMOUNT-1 phase 3 randomised controlled trial (Jastreboff et al., New England Journal of Medicine, 2022 — DOI: 10.1056/NEJMoa2206038). Figure shown is the treatment-regimen estimand for tirzepatide 15 mg at 72 weeks, alongside a lifestyle intervention. Results are from a clinical trial population; individual results will vary.
- STEP 1 phase 3 randomised controlled trial (Wilding et al., New England Journal of Medicine, 2021 — DOI: 10.1056/NEJMoa2032183). Figure shown is the treatment-regimen estimand for semaglutide 2.4 mg at 68 weeks, alongside a lifestyle intervention. Results are from a clinical trial population; individual results will vary.
- OASIS 4 phase 3 randomised controlled trial (New England Journal of Medicine, 2025). Figure shown is the treatment-regimen estimand for oral semaglutide 25 mg at 64 weeks, alongside a lifestyle intervention. Results are from a clinical trial population; individual results will vary.
- ATTAIN-1 phase 3 randomised controlled trial (New England Journal of Medicine, 2025). Figure shown is the treatment-regimen estimand for orforglipron 36 mg at 72 weeks, alongside a lifestyle intervention. Results are from a clinical trial population; individual results will vary.